SCHEMBL23877296

SCHEMBL23877296

COc1ccc2c(C(C)C)nc(OC)cc2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.46
CYP1A2 P05177 2/20 0.44
CYP2A6 P11509 1/20 0.44
RAB9A P51151 2/20 0.42
ABCB11 O95342 1/20 0.38
PTGS2 P35354 3/20 0.37
AKR1C3 P42330 3/20 0.37
AKR1C2 P52895 3/20 0.37
PTGS1 P23219 2/20 0.37
CDC42 P60953 1/20 0.37
RAC1 P63000 1/20 0.37
TSHR P16473 1/20 0.37
SLC22A6 Q4U2R8 1/20 0.37
CYP11B1 P15538 2/20 0.37
CYP11B2 P19099 2/20 0.37
NCF1 P14598 1/20 0.37
MEN1 O00255 2/20 0.36
ALDH1A1 P00352 2/20 0.36
KMT2A Q03164 2/20 0.36
DYRK1A Q13627 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27051691 0.82 NCF1 (0.46) CYP1A2CYP2A6RAB9ACYP11B1CYP11B2
SCHEMBL19386736 0.82 CYP1A2 (0.43) CYP1A2CYP2A6RAB9AABCB11PTGS2
SCHEMBL13883318 0.80 CYP1A2 (0.41) CYP1A2CYP2A6RAB9AABCB11AKR1C3
SCHEMBL13730041 0.79 L3MBTL1 (0.49) L3MBTL1CYP1A2CYP2A6RAB9AABCB11
SCHEMBL19388298 0.79 KDM4E (0.49) CYP1A2CYP2A6RAB9ATSHRCYP11B1
SCHEMBL18799597 0.78 CYP1A2 (0.34) L3MBTL1CYP1A2CYP2A6RAB9AABCB11
SCHEMBL26534221 0.77 L3MBTL1 (0.50) L3MBTL1CYP1A2CYP2A6RAB9ACYP11B1
SCHEMBL25873194 0.77 DYRK1A (0.48) L3MBTL1CYP1A2CYP2A6RAB9AALDH1A1
SCHEMBL8185328 0.76 L3MBTL1 (0.49) L3MBTL1CYP1A2CYP2A6RAB9ACYP11B1
SCHEMBL13830335 0.76 L3MBTL1 (0.49) L3MBTL1CYP1A2CYP2A6RAB9ACYP11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021194914-A1 SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER BRISTOL-MYERS SQUIBB COMPANY (US) 2021-09-30 WO disclosed